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The first case of human heme oxygenase (HO) - 1 deficiency was reported by Yachie et al. 
at our laboratory in 1999.1,2  In the present paper, I would like to review this novel disease.  Our 
studies into HO-1 deficiency were called by us "Kanazawa version Project X".  From the story of 
our successful discovery we have learned that serendipity is a very important spiritual factor.  
Serendipity is the making fortunate and unexpected discoveries by chance [from its possession by 
the heroes in the Persian fairy tale The Three Princes of Serendip]. 
 
Enzymology and molecular biology of HO 
 HO is the rate-limiting enzyme that adds an oxygen molecule to the porphyrin ring of heme, 
thereby catalyzing the oxidation of heme to biliverdin, free iron, and carbon monoxide (CO) (Figure 
1).  Biliverdin is subsequently metabolized to bilirubin by the enzyme biliverdin reductase.  By 
producing bilirubin, CO, and iron/ferritin, HO plays a crucial role in humans as a defense factor 
against a variety of oxidative stresses.3-7  
 Three isoforms of HO have been identified; HO-1, HO-2, and HO-3.3  Most interestingly, 
HO-1 is rapidly induced in liver, spleen, endothelium, and other tissues following exposure to 
various oxidative and other stresses.  In contrast, HO-2 is constitutively expressed and widely 
distributed in the body, especially in the brain and testes, at higher concentrations.   
The genes for human HO-1 and HO-2 have been isolated and mapped to chromosomes 
22q13.1 and 16p13.3, respectively.  HO-3, which has a high degree of amino acid identity to HO-2, 
is not present in humans and has been isolated only from rats.  The human HO-1 gene is about 
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 Clinical studies and laboratory data relating to the first case of HO-1 deficiency have 
previously been described in detail.1,2  Briefly, the male patient was born in 1992, and from the age 
of 2 suffered from recurrent high fever, xanthema, and hepatomegaly.  An elder sister and an elder 
brother are in good health, but the mother had previously had two intrauterine fetal deaths.  His 
birth weight was 2,029 kg at a gestational age of 38 weeks.  Growth retardation of -2 standard 
deviations was noted.  A mild motor developmental delay was apparent in infancy, but his 
intellectual development was approximately normal.  In addition to fever, rash, and hepatomegaly, 
arthralgia without swelling and generalized lymphadenopathy developed.  The saddle nose and 
frontal bossing of his face looked slightly strange, but no congenital disorder such as gargoylism was 
detected.  The lungs and heart showed no abnormalities, but asplenia was confirmed by abdominal 
ultrasonography and isotope image scanning. 
 One of the most characteristic findings in laboratory examinations was that normal clear 
serum was not obtained following centrifugation of peripheral blood samples, as illustrated in the 
original report, because of the presence of fragmented red blood cells in the blood.2  Giant platelets 
and numerous erythroblasts were noted, and dysmorphic monocytes were also observed.  There 
was a surface lipid layer following centrifugation of venous blood.  Hematuria and proteinuria were 
consistently present.  Severe microcytic hypochromic anemia was noted.  The numbers of white 
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blood cells and platelets were extraordinarily increased.  The CRP level was consistently high.  
Levels of lactate dehydrogenase and serum ferritin were remarkably increased.  Marked 
abnormalities of the coagulation/fibrinolysis system were noted.  Some adhesion molecules 
involved in vascular endothelial metabolism, including thrombomodulin, Von Willebrand factor, 
ICAM1, and selectins were also remarkably increased.  Autoantibodies were not detectable by 
Coombs’ test.  The serum heme concentration was extremely high as shown in the original paper.2  
Although intravascular hemolysis was strongly indicated, serum bilirubin levels were consistently 
within the normal range; serum haptoglobin levels, in contrast, remained extremely high.  
Hypertriglyceridemia and hypercholesterolemia were consistently observed.  Bone marrow 
aspiration showed no abnormal findings.  As far as hemolytic diseases are concerned, examinations 
including hemoglobin absorbance spectrum analysis and electrophoresis for hemoglobinopathies 
indicated no abnormalities.  Although the patient received aggressive therapeutic support, including 
frequent blood transfusions, he finally died of an intracranial hemorrhage at 6 years of age.  The 
autopsy report was published by Kawashima et al.8   
 The patient’s problem lists are shown in Table 1, these were (1) enhanced systemic 
inflammatory reactions, (2) intravascular hemolysis with erythrocyte-crushing symptom-complex, 
(3) marked abnormalities of the coagulation/fibrinolysis system, (4) nephropathy and systemic 
vascular endothelial disturbance, and (5) asplenia.   
 
Discovery of HO-1 deficiency  
 What on earth was the diagnosis for the patient?  A number of residents and doctors had 
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examined the patient and considered a diagnosis without success.  Second opinions had been 
pursued in many laboratories, even overseas, without any light being shed on the matter. 
 One day, I noticed once again a contradiction in the problem list which indicated that the 
patient had erythrocyte-crushing symptom-complex, with resultant intravascular hemolysis, and yet 
there was no elevation of the serum bilirubin level and the serum haptoglobin level had not declined 
to zero but, on the contrary, remained consistently high.  I opened my old biochemistry textbook 
and checked the metabolic map of heme through bilirubin.  I was reminded that two enzymes were 
involved in the pathway, HO and biliverdin reductase, and that HO was the important rate-limiting 
enzyme in heme metabolism.  This was indeed of great significance in enabling the project to 
advance to the next stage.  HO-1 had fortunately already been recognized by a number of 
biochemists as an important defense factor against oxidative stress in humans, and because of this the 
gene analysis had been completed and several antibodies were already on the market.  It was very 
fortunate that we were immediately able to prepare an antibody (antiserum) against HO-1 protein. 
 Immunohistochemical analysis using hepatic biopsy specimens demonstrated that, 
although intense HO-1 staining could be observed within Kupffer cells in control liver, no HO-1 
staining was detectable in the patient’s liver.  Transformed lymphoblastoid cell lines (LCLs) were 
then established from the HO-1-deficient patient.  Western immunoblotting analysis of HO-1 and 
HO-2 using LCLs clearly showed no HO-1 protein was produced by the patient’s LCLs, even after 
their subjection to oxidative stress by cadmium, arsenic trioxide and hemin (Figure 2).  HO-2 
protein was consistently noted in both the patient’s and control LCLs.2  
 Genetic analysis was performed immediately and revealed that the patient’s HO-1 gene 
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was completely lacking exon 2 in the maternal allele and had a two-nucleotide deletion within exon 
3 in the paternal allele.  Soon after, a large genomic deletion (1730 bp) including exon 2 in its 
entirety, probably mediated by homologous recombination with the Alu repeating sequence, was 
defined in the patient.9
 The paper regarding the first case of human HO-1 deficiency was published by Dr. A. 
Yachie as first author in the Journal of Clinical Investigation in 1999.2  Because this is the only case 
in the world to date, and there have thus been no further case reports, the complete nature of the 
disease has not been clarified.  There still remain several questions; for example, asplenia without 
cardiac anomalies has not previously been reported.  However, the discovery of the first patient 
with HO-1 deficiency has addressed the physiologically crucial role of HO-1 in the human body, and 
highlighted an academic breakthrough in the field of defense mechanisms against various oxidative 
stresses. 
 
HO-1 knockout mice 
 At least two strains of HO-1 knockout mice have been generated, by Poss and Tonegawa at 
the Massachusetts Institute of Technology10,11 and Yet et al. at Harvard Medical School.12  A 
comparison of clinical findings in the HO-1 deficient patient and HO-1 knockout mice is shown in 
Table 2; pathological findings have been described elsewhere.5  Although there are many 
similarities between the two species, including prenatal death, developmental failure, iron-deficiency 
anemia, and chronic systemic inflammatory disorders, almost the only difference between them is 
the occurrence of asplenia in the human HO-1 deficient patient which contrasts with the 
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splenomegaly observed in the knockout mice.   
             
Pathophysiology of human HO-1 deficiency 
 As illustrated in Figure 3, HO-1 deficiency results in a remarkable elevation of heme 
concentration and contrasting reductions in bilirubin, iron-binding ferritin, and CO.  Heme is one of 
the strongest oxidative stress agents, and low production of bilirubin and ferritin results in 
breakdown of the body’s defense system.  Clinically, disturbances of the iron-reuse system, 
functional disorders of hematological cells, especially monocytes/macrophages, and renal 
disturbances follow.  Low levels of CO production may be involved in homeostasis of the 
microvascular system.  Extreme disturbance of this system could lead to the complex features seen 
in the patient.    
 
HO-1 and monocytes/macrophages 
 HO-1 expression on the surface of monocytes in normal peripheral blood, but not 
lymphocytes, was remarkable.3,13,14  Monocytes from the patient with HO-1 deficiency showed 
remarkable morphological changes, with abnormal surface antigens including HLA-DR, CD36, and 
CD11b, as shown previously.3,14  A disturbance of phagocytic function was also observed in the 
patient.  These findings indicate that HO-1 plays a crucial role in monocyte function, and that the 
HO-1 defect resulted in the severe systemic inflammation that occurred in the patient.   
 Recently, several subpopulations of peripheral blood monocytes have been separated in our 
laboratory on the basis of their expression of surface antigens such as CD14, CD16, and CCR2, their 
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production of cytokines such as IL-6 and TNF-α, and their functional roles in vivo.15  We 
demonstrated the selective expansion of a subpopulation of circulating monocytes that preferentially 
produced HO-1 during the acute phase of infectious diseases including Kawasaki disease and 
influenza virus infection.13,15
 A beautiful review in Trends in Immunology showed how the induction of excessive HO-1 
or CO expression in normal monocytes and macrophages could suppress the proinflammatory 
response while, at the same time, boosting the anti-inflammatory response in the 
lipopolysaccharide-stimulating system (Figure 4).16  Another review described how the HO-1 
molecule also plays a role in the regulation of regulatory T cell and antigen-presenting cell function 
via interferon-γ production (Figure 5).17   
 
HO-1 and renal diseases 
 Three renal specimens from the patient were examined, two renal biopsies and a third 
sample obtained at autopsy.18  The tubulointerstitial damage was striking.  The size of the injured 
area progressively increased, occupying 0.7% of the first biopsy, 17.4% of the second, and 40.2% of 
the autopsy sample, as described previously.18  Using immunohistochemical analysis, 
moderate-to-intense HO-1 expression was observed within the tubular epithelial cells in various 
renal diseases, but was not detected within intrinsic glomerular cells.19  HO-1 staining tended to be 
more intense within distal tubules than proximal tubules.  It was intriguing that characteristic HO-1 
staining was also noted in a patient with minimal change nephrotic syndrome in remission, in which 
no apparent tubular damage is usually seen.  These findings indicate that renal tubular epithelial 
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cells are constantly exposed to various toxic stresses.  Within the proximal tubules, higher degrees 
of HO-1 expression correlated significantly with greater degrees of proteinuria and hematuria.19   
Further studies using in situ hybridization methods showed that HO-1 mRNA was readily 
detectable within tubular cells, and even within glomerular and Bowman’s epithelial cells with lesser 
intensity.20  Different patterns of HO-1 gene expression were also observed between proximal and 
distal tubules .  Further experimental studies were performed to compare the patterns of oxidative 
stress-induced HO-1 expression between primary cultured human mesangial cells (HMC) and renal 
proximal tubular epithelial cells (HRPTEC).21  The results showed that HO-1 mRNA expression 
and protein production by HMC peaked earlier, at 4 h to 6 h after hemin stimulation, and that the 
levels of each declined rapidly compared with HRPTEC.21  These findings indicate that HO-1 
expression is regulated in a manner that is cell-, tissue-, organic segment-, and stress antigen-specific.  
 
HO-1 and endothelial cell injuries  
Although there were no significant changes in the walls of major vessels in autopsy 
specimens from the patient, with no necrotic changes and no cell infiltration or fibrosis,8 laboratory 
data strongly suggested systemic vascular endothelial cell injury with massive intravascular 
hemolysis.2  Interestingly, electron microscopic examination revealed widespread endothelial 
detachment and subendothelial deposits of unidentifiable material in the renal glomerular capillary 
loops as shown previously.2  We may therefore propose that HO-1 deficiency constitutes a novel 
form of vasculitis or endothelial cell injury syndrome encompassing a wide variety of clinical 
manifestations.3  The unexpected occurrence of endothelial cell injury without major changes to the 
 10
vessels might be related to the monocyte/macrophage dysfunction in HO-1 deficiency.3   
 
HO-1 and cardiovascular disorders 
Recent advances in vascular biology have revealed that HO-1 is markedly involved in 
cardiovascular homeostasis and systemic vascular disease.23,24  Oxidative modification of 
low-density lipoprotein (LDL) in the subendothelial space is recognized as an early event in 
atherogenesis.23  Endothelial cell dysfunction then accelerates the adherence of 
monocytes/macrophages and T lymphocytes to the endothelium, and macrophages become foam 
cells after the accumulation of lipid in combination with T cells and smooth muscle cells.  The 
proliferation of intimal smooth muscle cells is known to be a key event in the development of 
advanced atherosclerosis.  A large number of growth factors and cytokines participate in this 
process, and it is suggested that HO-1 regulates the system.  HO-1 may inhibit the development of 
atherosclerosis via the upregulation or downregulation of specific molecules at various stages.23  
Importantly, special analysis of plasma from the HO-1-deficient patient revealed ongoing in vivo 
heme-catalyzed LDL oxidation.7,24  In addition, increased cytotoxicity induced by heme-catalyzed 
oxidation of LDL in the patient’s lymphoblastoid cells was demonstrated.24   
HO-1 protects the heart.25  Right ventricular dilatation and thrombus formation were 
reported in HO-1 knockout mice in response to hypoxia.12  In xenograft heart transplantation 
experiments, such as from mouse-to-rat, only transplanted hearts able to express HO-1 survived 
indefinitely.  Lack of the gene led to rejection in just a few days.  If, however, both donor and 
recipient were treated with CO, the transplanted heart survived in the long-term.26
 11
HO-1 is speculated to play another important role in angiogenesis.27  HO-1 knockout mice 
have hypoplastic arteries when compared with controls.28  We need to carefully evaluate the 
asplenia in the patient with HO-1 deficiency.  Asplenia without heart anomalies, as in the patient, 
might suggest a hypothesis whereby HO-1 gene expression is correlated with splenogenesis and/or 
splenic arteriogenesis in the fetus.    
 
HO-1 and pulmonary disease     
We have observed that HO-1 expression in lung is localized in the peribronchiolar 
epithelium and blood vessel endothelial cells, as well as in alveolar macrophages (unpublished data).  
HO-1 expression was much more intense in lung specimens from patients with secondary 
pulmonary hypertension than from those with congenital primary pulmonary hypertension 
(unpublished data).  The involvement of HO-1 in respiratory conditions such as experimental 
bronchial asthma29 and oxidant-induced lung injury in mice has been described.30   
 
Polymorphism within the HO-1 promoter region 
 The next thing to summarize is that the cytoprotective effect of HO-1 is associated with GT 
repeat polymorphism in the promoter region of the gene.  A 20 to 30 GT repeat polymorphism has 
been described.31  Individuals with shorter GT repeats are known to have a reduced risk of 
restenosis after angioplasty.32  HO-1 gene promoter polymorphism has been shown to be associated 
with renal allograft function.33  A higher frequency of pulmonary emphysematous lesions has also 
been noted in cigarette smokers with a longer GT repeat.34  In terms of the biological mechanism 
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underlying these associations, in vitro studies of lymphoblastoid cell lines have indicated that HO-1 
gene polymorphism is associated with the strength of the antiapoptotic effect of HO-1 in response to 
oxidant-induced stresses.35
 
HO-1 and nervous system 
 Like haptoglobin, hemopexin is another plasma protein that binds heme with high affinity.  
Although the monocyte/macrophage protein CD163 is known to be a scavenger receptor for 
hemoglobin/haptoglobin,36 the hemopexin-heme complex is cleared from the circulation by the 
low-density lipoprotein receptor-related protein (LRP)/CD91 (Figure 6).37  Hemopexin is abundant 
in cerebrospinal fluid.  In addition to its expression in macrophages, LRP/CD91 is highly expressed 
in several other cell types, such as neurons.37  Hence, HO-1 induced after heme uptake by 
LRP/CD91 appears to play a key role in neurodegenerative diseases such as Alzheimer disease.38  
A protective effect of HO-1 in cerebral vascular impairment in rats has been reported.39   
 
HO-1 gene transfection and hemin-induced cell injury of transfected cells 
 Transfection of the HO-1 gene into LCLs from the patient were performed using a 
retroviral vector.3,13  Positive expression of HO-1 protein by the transfected LCLs was confirmed 
by flow cytometry and immunohistochemistry.  However, the HO-1 expression pattern in the 
transfected LCLs was constitutive but not inducible, as shown physiologically.  When 
HO-1-transfected LCLs were stimulated by different concentrations of hemin, significant inhibition 
of cell injury was observed in a dose-dependent manner, in contrast to untransfected LCLs from the 
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patient which were seriously injured.3,13  Inhibition of cell injury was also confirmed in our 
laboratory using an HO-1-transfected anchorage-dependent ECV304 cell line.40  Among the 
different clones of HO-1-transfected ECV304 cells, those expressing a moderate level of HO-1 
showed enhanced cell survival under oxidative stress compared with wild-type cells.  In contrast, 
however, a representative clone expressing a high level of HO-1 exhibited enhanced cell injury, 
suggesting that excessive levels of HO-1 exerted a paradoxical effect on cell survival.40  This might 
well be because, despite constitutive expression of the HO-1 gene in both ECV304 and patient LCL 
HO-1-transfected cell lines, there is no stress-inducible expression that is recognized physiologically.  
This suggests that consideration should be given to physiologically-recognized stress-inducible 
HO-1 gene expression in future gene therapy trials.   
 
HO-1 as a “therapeutic funnel” 
 HO-1 has been described as a “therapeutic funnel”.16  As shown in Figure 7, a number of 
molecules exert their effect by “feeding through” HO-1, and induce and activate HO-1.  The 
products of HO-1 activity, biliverdin/bilirubin, CO, and free-Fe/ferritin then provide the protective 
effects.  Collectively, HO-1 serves as a “protective” gene by virtue of its anti-inflammatory, 
anti-apoptotic, and anti-proliferative actions.  Clinically, HO-1 has attracted widespread attention in 
various fields, including cardiovascular ischemia and reperfusion injury, as well as atherosclerosis, 
hypertension, and systemic inflammatory, renal, and nervous disorders, as described above.  
Examination of PubMed shows an almost two-fold increase in the number of publications regarding 




 The discovery of the novel disease, HO-1 deficiency, was rather like the story of 
“Columbus’ egg” when we took a backward glance.  “Columbus’ egg” means the tradition that 
Columbus stood a raw egg on its end on the table; a thing that looks easy once it has been done.  
Hemolysis, hypobilirubinemia, and hyperhaptoglobulinemia were actually the three key words that 
led to elucidation of the new disease.  My memory is still strong of the moment we observed that 
the Kupffer cells of the patient showed no HO-1 staining, suggesting a novel disease.  Why did no 
one turn their attention to HO-1 more speedily?  Is there any idea how to stimulate the faculty of 
finding valuable or agreeable things not sought for more promptly?   
 Before finishing this review, I would like to think about serendipity.  Recently, brain 
scientists have paid special attention to serendipity; the faculty of making fortunate and unexpected 
discoveries by chance [named after its possession by the heroes in the Persian fairy tale The Three 
Princes of Serendip.]  How can we combine an unexpected chance with something that is valuable?  
It has been said that this depends on continuous mental exercise targeting the brain that involves at 
first moving into action, followed by continuous observation and daily concentration on the relevant 
questions.  Secondly, it is very important for us to be aware of even trifling matters and, finally, not 
to give up, but to accept things as they are.  The proverbs say “Take time by the forelock, for he is 
bald behind” and “Opportunity seldom knocks twice at any man’s door.”  Another proverb says, 
“Chance finally is delivered to the person possessing superior knowledge and excellent technology.”   
 We have to continually think about serendipity, allowing our minds to act, observe, and 
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accept things, without discarding them because they are small.  We will then be able to succeed in 
breaking through the problems, as was the case, for example, with the discovery of the novel disease, 
human HO-1 deficiency.   
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Problem lists of the patient 
---------------------------------------------------------------------------------------- 
1) Generalized inflammation 
2) Intravascular hemolysis with marked fragmentation of erythrocytes 
3) Coagulation/fibrinolysis system disturbance 










Comparison of clinical findings in the HO-1-deficient patient and HO-1 knockout mice 
＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿ 
Finding Human Mice 
＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿ 
Intrauterine death Stillbirth, abortion 20% birth rate 
Growth failure + + 
Anemia  + + 
Fragmentation + Unknown 
Iron-binding capacity Increased Increased 
Ferritin Elevated Elevated 
Iron deposition + + 
Hepatomegaly + + 
Splenomegaly Asplenia + 
Lymph node swelling + + 
Leukocytosis + + 
Thrombocytosis + Unknown 
Coagulation abnormality + Unknown 
Endothelial injury + Unknown 
Hyperlipidemia + Unknown 
＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿＿ 





1. Metabolic map of porphyrin through bilirubin 
2. Western blotting analysis using lymphoblastoid cell lines (LCLs) 
3. Pathophysiology of HO-1 deficiency 
4. Heme oxygenase-1 and monocytes/macrophages in pro- and anti-inflammatory systems (modified 
in part from Trends in Immunology 2003; 24: 449-55) 
5. Heme oxygenase-1 in the system of influence of interferon-γ production by T regulatory cells on 
the antigen presenting cell function (modified in part from Trends in Immunology  
www.sciencedirect.com, 2006) 
6. Overview of receptor pathways for the endocytosis of extracellular heme and hemoglobin in 
complex with hemopexin and haptoglobin (modified in part from Blood 2005; 106: 2572-9) 







































































Control 1 Patient Control 2 Control  3
none As none none none AsAsAs
Western Blotting Analysis
Control
















































HO-1 as a “ therapeutic funnel ”
IL-10 NO
Biliverdin/
Bilirubin CO
Protection
Fe2+/Ferritin
15-PGJ2
ＨＳＰHSP
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